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the clinic using a Brazilian Portuguese Health Utilities Index
self-report questionnaire. Responses were converted to attribute
levels, and utility scores for morbidity in individual health
attributes and for overall HRQL, using standard HUI Decision
Tables and Utility Functions. Standard t-tests and 1-way ANOVA
were used to analyze HUI3 utility scores within and across diag-
noses and between countries. HUI3 overall HRQL scores were
categorized to mild / moderate / severe disability (1.00 = No
disability, 0.89–0.99 = Mild, 0.70–0.88 = Moderate, <0.70 =
Severe disability). RESULTS: A total of 138 consecutive survivors
participated in the survey. More than 71% reported some disabil-
ity (mild-moderate-severe). More than one-third reported some
cognitive disability and/or pain while approximately one-quarter
reported problems with vision, speech or emotion. As hypoth-
esized, retinoblastoma survivors had signiﬁcant visual morbidity
(p = 0.048). Survivors of germ cell tumors had signiﬁcant pain
morbidity (p = 0.003) and lowest meanHRQL utility score (0.49)
among the diagnostic groups. HRQL means of survivors were
similar (p > 0.05) among countries (Brazil, Canada, Central
America, Uruguay) within diagnostic groups of acute lymphoblas-
tic leukemia and hodgkin’s disease. CONCLUSION: The results
show that the Brazilian survivors experience a wide range of
disabilities and impaired HRQL similar to those reported in other
countries and afﬁrm the construct validity of the HUI3.
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OBJECTIVE: To determine the difference in survival quality of
patients treated according to two major treatment strategies for
ALL in childhood, for use in a cost-utility study. METHODS:
Children diagnosed with ALL between 1985 and 2003, and
treated in one of ﬁve centers according to a DFCI or BFM-based
protocol, were eligible if they were alive at least two years
post-therapy. Parents of eligible survivors, in a cross-sectional
survey, were asked to complete a Health Utilities Index (HUI)
15-item self-complete questionnaire with a ‘past 1-week’ recall
period. HUI3 health-related quality of life (HRQL) and single-
attribute scores were determined for each patient according to
standard algorithms. Chi-square was used to test for differences
in confounding factors between study groups: gender, and age at
diagnosis (in quintiles). Differences in mean HRQL and single-
attribute scores between DFCI and BFM groups were tested
using one-way ANOVA. Statistical signiﬁcance was set at
p < 0.05. RESULTS: 612 parent assessments were available for
analysis: 463 for DFCI survivors and 188 for BFM survivors. No
signiﬁcant differences between DFCI and BFM survivors were
detected for proportion of males and females (p > 0.079), and
age at diagnosis (p > 0.243). There were no signiﬁcant differences
detected between DFCI and BFM survivors in mean single-
attribute or HRQL scores (p > 0.176). The mean HRQL score
was 0.90 (SD = 0.166) for DFCI survivors, 0.92 (SD = 0.140) for
BFM survivors, and 0.91 (SD = 0.159) for the pooled set of
survivors. CONCLUSION: Clinical research has reported previ-
ously that there is no signiﬁcant difference in mortality rates
between DFCI and BFM treatment strategies. These HRQL
results indicate that survivors of these treatment strategies also
do not experience a difference in quality of survival. Future work
for the cost-utility study will focus on the incremental HRQL of
patients during phases of active therapy and the costing of
hospital-based health care services.
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OBJECTIVE:Determine the impact of testing for high prevalence,
low penetrance gene variants associated with colorectal cancer
(polymorphisms, haplotypes) on a person’s quality of life (QOL),
health habits, and cancer screening intentions.METHODS: First-
degree relatives of colorectal cancer patients and a matched group
of persons without a family history of colorectal cancer from the
Colorectal Cancer Familial Registry—a population-based registry
in Washington State—were invited in 2006–7 to participate in a
web-based survey of testing for gene variants associated with
colorectal cancer risk. Participants were asked how such tests
might inﬂuence their QOL, health habits, and intent to obtain
colorectal cancer screening. RESULTS: A total of 310 relatives
and 170 persons without a family colorectal cancer history com-
pleted the questionnaire. For the positive genetic test scenario,
69% of respondents stated they would be “somewhat worried”;
18% said they would be “very worried.” QOL measured by the
standard gamble for the carrier state was modestly lower than
current health; the difference was signiﬁcant only for relatives (no
relatives with colorectal cancer 0.89 vs. 0.88, p = 0.11; relatives
with colorectal cancer 0.90 vs. 0.88, p = 0.02). The difference in
QOL was not signiﬁcant after adjustment for sociodemographic
and health factors. In the positive gene test scenario, 30% of
respondents stated they would change their diet substantially,
25% would increase exercise, and 43% would start colorectal
cancer screening. Relatives of colorectal cancer patients did not
differ signiﬁcantly from those without a family history in their
reported intent to change these behaviors. CONCLUSION:
Testing for high prevalence gene variants associated with colorec-
tal cancer risk may increase cancer worry while only modestly
inﬂuencing overall QOL. Testing could improve cancer preventive
health habits and colorectal cancer screening adherence. The
ﬁndings suggest that testing might reduce colorectal cancer inci-
dence, particularly among those at higher risk for colorectal
cancer.
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OBJECTIVE: Adult chronic immune thrombocytopenic purpura
(ITP) is characterized by autoimmune-mediated platelet destruc-
tion and suboptimal platelet production. Signs and symptoms
can range from bruising to gastrointestinal and intracranial
bleeding. The disease may therefore impact one’s health-related
quality of life (HRQoL). We quantiﬁed the burden of ITP on
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